Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study

Danbee Kang, Im-Ryung Kim, Eun-Kyung Choi, Young Hyuck Im, Yeon Hee Park, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Hae Kwang Lee, Ji-Hye Park, Dong-Youn Lee, Mario E Lacouture, Eliseo Guallar, Juhee Cho, Danbee Kang, Im-Ryung Kim, Eun-Kyung Choi, Young Hyuck Im, Yeon Hee Park, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Hae Kwang Lee, Ji-Hye Park, Dong-Youn Lee, Mario E Lacouture, Eliseo Guallar, Juhee Cho

Abstract

Background: Although chemotherapy-induced alopecia (CIA) is considered temporary, some patients report persistent alopecia several years after chemotherapy. There is, however, a paucity of long-term prospective data on the incidence and impact of permanent CIA (PCIA). The objective of our study was to estimate the long-term incidence of PCIA in a cohort of patients with breast cancer whose hair volume and density were measured prior to chemotherapy and who were followed for 3 years after chemotherapy.

Materials and methods: Prospective cohort study of consecutive patients ≥18 years of age with postoperative diagnosis of stage I-III breast cancer expected to receive adjuvant chemotherapy at the outpatient breast cancer clinic at the Samsung Medical Center in Seoul, Korea, from February 2012 to July 2013 (n = 61). Objective hair density and thickness were measured using a noninvasive bioengineering device.

Results: The proportion of participants who had PCIA at 6 months and 3 years was 39.5% and 42.3%, respectively. PCIA was characterized in most patients by incomplete hair regrowth. Patients who received a taxane-based regimen were more likely to experience PCIA compared with patients with other types of chemotherapy. At a 3-year follow-up, hair thinning was the most common problem reported by study participants (75.0%), followed by reduced hair volume (53.9%), hair loss (34.6%), and gray hair (34.6%).

Conclusion: PCIA is a common adverse event of breast cancer adjuvant cytotoxic chemotherapy. Clinicians should be aware of this distressing adverse event and develop supportive care strategies to counsel patients and minimize its impact on quality of life.

Implications for practice: Knowledge of permanent chemotherapy-induced alopecia, an under-reported adverse event, should lead to optimized pretherapy counseling, anticipatory coping techniques, and potential therapeutic strategies for this sequela of treatment.

Keywords: Alopecia; Breast neoplasm; Chemotherapy; Cohort.

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

© AlphaMed Press 2018.

Figures

Figure 1.
Figure 1.
Incidence of PCIA at 6 months and 3 years after completion of chemotherapy. Abbreviations: m, months; PCIA, permanent chemotherapy‐induced alopecia; y, years.
Figure 2.
Figure 2.
Average hair density (A, B) and thickness (C, D) during follow‐up. Abbreviations: AC, doxorubicin, cyclophosphamide; FAC, fluorouracil, doxorubicin, cyclophosphamide; T1, before chemotherapy; T2, after two cycles of chemotherapy; T3, 1 month after completion of chemotherapy; T4, 3 months after completion of chemotherapy; T5, 6 months after completion of chemotherapy; T6, 3 years after completion of chemotherapy.
Figure 3.
Figure 3.
Representative photographs of a patient's mid‐frontal hair before chemotherapy and 3 years after completion of chemotherapy. (A): ×15. (B): ×60.

References

    1. Yabroff KR, Lawrence WF, Clauser S et al. Burden of illness in cancer survivors: Findings from a population‐based national sample. J Natl Cancer Instit 2004;96:1322–1330.
    1. Nissen MJ, Swenson KK, Ritz LJ et al. Quality of life after breast carcinoma surgery: A comparison of three surgical procedures. Cancer 2001;91:1238–1246.
    1. Zielinski C, Beslija S, Mrsic‐Krmpotic Z et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first‐line chemotherapy in metastatic breast cancer: A Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial. J Clin Oncol 2005;23:1401–1408.
    1. Kim IR, Cho JH, Choi EK et al. Perception, attitudes, preparedness and experience of chemotherapy‐induced alopecia among breast cancer patients: A qualitative study. Asian Pac J Cancer Prev 2012;13:1383–1388.
    1. McGarvey EL, Baum LD, Pinkerton RC et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001;9:283–289.
    1. Paus R, Haslam IS, Sharov AA et al. Pathobiology of chemotherapy‐induced hair loss. Lancet Oncol 2013;14:e50–e59.
    1. Grevelman EG, Breed WP. Prevention of chemotherapy‐induced hair loss by scalp cooling. Ann Oncol 2005;16:352–358.
    1. Hesketh PJ, Batchelor D, Golant M et al. Chemotherapy‐induced alopecia: Psychosocial impact and therapeutic approaches. Support Care Cancer 2004;12:543–549.
    1. Sredni B, Xu RH, Albeck M et al. The protective role of the immunomodulator AS101 against chemotherapy‐induced alopecia studies on human and animal models. Int J Cancer 1996;65:97–103.
    1. Bleiker TO , Nicolaou N, Traulsen J et al. ‘Atrophic telogen effluvium’ from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin d analogue in humans. Br J Dermatol 2005;153:103–112.
    1. Shin H, Jo SJ, Kim DH et al. Efficacy of interventions for prevention of chemotherapy‐induced alopecia: A systematic review and meta‐analysis. Int J Cancer 2015;136:E442–E454.
    1. van den Hurk CJ, Peerbooms M, van de Poll‐Franse LV et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients ‐ results of the Dutch Scalp Cooling Registry. Acta Oncol 2012;51:497–504.
    1. Komen MMC, Smorenburg CH, van den Hurk CJ et al. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy‐induced alopecia. The Oncologist 2013;18:885–891.
    1. Nangia J, Wang T, Osborne C et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial. JAMA 2017;317:596–605.
    1. van den Hurk CJ, van den Akker‐van Marle ME, Breed WP et al. Cost‐effectiveness analysis of scalp cooling to reduce chemotherapy‐induced alopecia. Acta Oncol 2014;53:80–87.
    1. Paus R, Haslam IS, Sharov AA et al. Pathobiology of chemotherapy‐induced hair loss. Lancet Oncol 2013;14:e50–e59.
    1. Sinn DH, Cho EJ, Kim JH et al. Current status and strategies for viral hepatitis control in Korea. Clin Mol Hepatol 2017;23:189–195.
    1. Kang D, Choi EK, Kim IR et al. Distress and body image due to altered appearance in posttreatment and active treatment of breast cancer patients and in general population controls. Palliat Support Care 2018;16:137–145.
    1. Kluger N, Jacot W, Frouin E et al. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: A prospective study of 20 patients. Ann Oncol 2012;23:2879–2884.
    1. Lee SH, Kang JS, Jeon IK et al. Two‐point scoring method for the evaluation of pattern hair loss by phototrichogram using a headband and a tapeline. Skin Res Technol 2013;19:183–188.
    1. Freites‐Martinez A, Shapiro J, Chan D et al. Endocrine therapy‐induced alopecia in patients with breast cancer. JAMA Dermatol 2018;154:670–675.
    1. Rogiers V; EEMCO Group . EEMCO guidance for the assessment of transepidermal water loss in cosmetic sciences. Skin Pharmacol Appl Skin Physiol 2001;14:117–128.
    1. Yun YH, Bae SH, Kang IO et al. Cross‐cultural application of the Korean version of the European Organization for Research and Treatment of Cancer (EORTC) Breast‐Cancer‐Specific Quality of Life Questionnaire (EORTC QLQ‐BR23). Support Care Cancer 2004;12:441–445.
    1. Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy‐induced alopecia: Case report and review of the literature. J Am Acad Dermatol 2010;63:333–336.
    1. Prevezas C, Matard B, Pinquier L et al. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 2009;160:883–885.
    1. Kim SN, Lee SY, Choi MH et al. Characteristic features of ageing in Korean women's hair and scalp. Br J Dermatol 2013;168:1215–1223.
    1. Kang D, Choi EK, Kim IR et al. Distress and body image due to altered appearance in posttreatment and active treatment of breast cancer patients and in general population controls. Palliat Support Care 2018;16:137–145.
    1. Palamaras I, Misciali C, Vincenzi C et al. Permanent chemotherapy‐induced alopecia: A review. J Am Acad Dermatol 2011;64:604–606.
    1. Fonia A, Cota C, Setterfield JF et al. Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients. J Am Acad Dermatol 2017;76:948–957.
    1. Choi EK, Kim IR, Chang O et al. Impact of chemotherapy‐induced alopecia distress on body image, psychosocial well‐being, and depression in breast cancer patients. Psychooncology 2014;23:1103–1110.
    1. Cocks K, King MT, Velikova G et al. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 2008;44:1793–1798.
    1. Rugo HS, Klein P, Melin SA et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 2017;317:606–614.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere